We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

SARS-CoV-2 Neutralizing Antibodies Fade Quickly in Recovering COVID-19 Patients After Symptoms Subside

By HospiMedica International staff writers
Posted on 19 Oct 2020
Print article
Illustration
Illustration
SARS-CoV-2 antibody levels in the blood of COVID-19 patients decline rapidly during the weeks after their bodies have cleared the virus and symptoms have subsided, according to a new study.

Researchers at the University of Montreal (Montreal, QC, Canada) are attempting to understand how the levels of antibodies change over time in order to optimize the use of blood plasma from recovering patients for treating those with severe COVID symptoms. Their research is also critical for understanding the efficacy of COVID-19 vaccines and finding out whether previously infected people face a risk of re-infection. Previous studies have revealed that antibodies against the SARS-CoV-2 spike protein peak two or three weeks following the onset of symptoms. In an earlier study of more than 100 patients by researchers at the University of Montreal, it was found that plasma’s ability to neutralize the SARS-CoV-2 virus declined significantly between three and six weeks after the onset of symptoms.

In the new longitudinal study, the team analyzed blood samples collected at one-month intervals from 31 individuals who were recovering from COVID-19. The researchers measured the levels of immunoglobulins that act against the coronavirus S protein and tested the ability of the antibodies to neutralize SARS-CoV-2. They found that the levels of Immunoglobulins G, A, and M that target the binding site declined between six and 10 weeks after the onset of symptoms and the ability of the antibodies to neutralize the virus also reduced over the same period.

Small studies have found that convalescent plasma can reduce the severity of illness and reduce hospitalization in COVID-19 patients, but it is yet to demonstrate benefits in randomized trials. Recovering patients cannot donate blood until at least 14 days after symptoms have subsided in order to allow their body to clear the viral particles, although the researchers have concluded that convalescent plasma must be collected during a specific window of time after recovery for deriving any clear benefits.

“We don’t want to transfuse the virus, just transfuse the antibodies,” said Andrés Finzi, Ph.D., at the University of Montreal. “But at the same time, our work shows that the capacity of the plasma to neutralize viral particles is going down during those first weeks.”

Related Links:
University of Montreal

Gold Member
12-Channel ECG
CM1200B
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Bronchoscopy Head Support
Reison 10-330

Print article

Channels

Critical Care

view channel
Image: The stretchable microneedle electrode arrays (Photo courtesy of Zhao Research Group)

Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment

The field of personalized medicine is transforming rapidly, with advancements like wearable devices and home testing kits making it increasingly easy to monitor a wide range of health metrics, from heart... Read more

Surgical Techniques

view channel
Image: NeuroBlate NB3 FullFire 1.6mm laser probe is meant for use with the NeuroBlate System (Photo courtesy of Monteris Medical)

World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets

A new probe enhances the ablation capabilities for a broad spectrum of oncology and epilepsy targets, including pediatric applications, by incorporating advanced laser and cooling technologies to support... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more